Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

If the Wolverines can close with Haywood, they would finish with four top-50 recruits. They didn’t sign any the previous two ...

Foreign portfolio investors (FPIs) sold shares worth Rs 3,958.37 crore, while domestic institutional investors (DIIs) were net buyers to the tune of Rs 2,708.23 crore in the Indian equity market on 3 ...

Despite a wave of garment factory closures in Bangladesh, export earnings from the sector continue to rise, raising questions ...

Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets ...

Looking ahead TEAM represents a bold step toward making episode-based payment a permanent feature of hospital reimbursement. The model's mandatory participation, regional pricing approach, and ...

Over the past few years, tech stocks have seen dramatic shifts driven by high-stakes mergers and acquisitions, with strategic ...

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients ...

Prime Minister Justin Trudeau says U.S. President Donald Trump has agreed to pause tariffs for 30 days after a Monday ...

NEW YORK, Feb. 3 (Xinhua) -- U.S. stocks ended lower on Monday. The Dow Jones Industrial Average fell 122.75 points, or 0.28 percent, to 44,421.91. The S&P 500 sank 45.96 points, or 0.76 percent, to 5 ...

U.S. stocks ended lower on Monday, as investors reacted to the Donald Trump administration's planned tariff rollout.